GILD · News · 20260907N

Regulatory Approval Milestones

GILEAD SCIENCES, INC. · 2026-09-07 · Importance 47 · Surprise 60 · In source text

The FDA approved Bixlenvo, a once-daily single-tablet regimen for virologically suppressed adults with HIV. Bixlenvo combines bictegravir 75 mg with lenacapavir 50 mg and is positioned as the first and only single-tablet regimen for patients on complex regimens who cannot use other available single-tablet options. Treatment requires a two-day initiation dose with Sunlenca, expanding Gilead’s HIV product portfolio and transition opportunities.

Key facts

• The FDA approved Gilead's Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a new once-daily single tablet regimen for virologically suppressed adults with HIV. source
• The FDA approval of Bixlenvo marks the first and only single-tablet regimen option for individuals on complex regimens who cannot use other available single tablet regimens. source
• Bixlenvo combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a first-in-class capsid inhibitor, and requires a two-day initiation dose with Sunlenca. source

Impact estimates